Rubius Therapeutics, Inc.
RUBYDelisted Mar 28, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001709401
Rubius Therapeutics, Inc. was delisted on Mar 28, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 42 institutions reported holding it in 13F filings for Q4 2022, worth $11.2M in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in Rubius Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 108
- +3 vs. Q1 2021
- Shares held
- 85.6M
- +1.59M (+1.9%) vs. Q1 2021
- Total value
- $2.09B
- −$136.9M (−6.2%) vs. Q1 2021
- New holders
- 24
- 44 more added
- Sold out
- 21
- 23 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RUBY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 7 | $61.3K |
| Q4 2022 | 42 | $11.2M |
| Q3 2022 | 62 | $29.7M |
| Q2 2022 | 73 | $66.6M |
| Q1 2022 | 117 | $493.9M |
| Q4 2021 | 108 | $863.6M |
| Q3 2021 | 105 | $1.55B |
| Q2 2021 | 108 | $2.09B |
| Q1 2021 | 105 | $2.23B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Rubius Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 2,361,088 | $57.6M | 0.01% | +98,589+4.4% | Added |
| State Street Corp | 2,440,295 | $59.6M | 0.00% | +1,798,409+280.2% | Added |
| Vanguard Group Inc | 3,242,403 | $79.1M | 0.00% | +143,801+4.6% | Added |
| BlackRock Inc. | 3,435,835 | $83.9M | 0.00% | −201,782−5.5% | Reduced |
| Artal Group S.A. | 4,633,791 | $113.1M | 2.57% | −250,000−5.1% | Reduced |
| Baillie Gifford & Co | 4,695,022 | $114.6M | 0.06% | +1,1510.0% | Added |
| FMR LLC | 13,527,493 | $330.2M | 0.03% | 00.0% | Unchanged |
| Flagship Pioneering Inc. | 38,506,526 | $939.9M | 12.01% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −550,000−100.0% | Sold out |
| Compagnie Lombard Odier SCmA | 0 | $0 | 0.00% | −163,172−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −138,913−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −82,728−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −74,200−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −63,000−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −43,050−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −28,442−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −26,903−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −20,334−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −17,000−100.0% | Sold out |
| Caas Capital Management LP | 0 | $0 | 0.00% | −13,271−100.0% | Sold out |
| Euclidean Capital LLC | 0 | $0 | 0.00% | −12,791−100.0% | Sold out |
| Jefferies Group LLC | 0 | $0 | 0.00% | −8,500−100.0% | Sold out |
| CSS LLC | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −1,477−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −349−100.0% | Sold out |
| Mascoma Wealth Management LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −113−100.0% | Sold out |